Biotech issuance surges as Covid-19 brings demand for innovation

By Sam Kerr
30 Jun 2020

Equity issuance has surged during the Covid-19 pandemic in both Europe and the US, and one of the sectors that has printed the most stock in the first half of the year is the biopharmaceuticals industry. In the rush for healthcare innovation, banks say they are busy lining up more deals for the second half.

According to Dealogic data, biotech ECM issuance in North America and EMEA grew by 175% in the first half of the year, compared with the first half of 2019. The sector was the second largest in terms of issuance in the US and Europe and the largest in ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial